{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:46:37Z","timestamp":1776761197031,"version":"3.51.2"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":388,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Health Youth Talent Project of Shanghai Municipal Health Commission","award":["2022YQ023"],"award-info":[{"award-number":["2022YQ023"]}]},{"name":"Shanghai Municipal Health Commission Clinical Research Project","award":["20214Y0152"],"award-info":[{"award-number":["20214Y0152"]}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82170388"],"award-info":[{"award-number":["82170388"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82370300"],"award-info":[{"award-number":["82370300"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Technology Research Leader Program","award":["21XD1434700"],"award-info":[{"award-number":["21XD1434700"]}]},{"name":"Cardiac rehabilitation fund by the International Medical Exchange Foundation","award":["Z-2019-42-1908-3"],"award-info":[{"award-number":["Z-2019-42-1908-3"]}]},{"name":"Grant for the Construction of Innovative Flagship Hospital for Integrated Traditional Chinese and Western Medicine","award":["ZY(2021\u20132023)-0205\u201305"],"award-info":[{"award-number":["ZY(2021\u20132023)-0205\u201305"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We aim to elucidate the association of baseline eGFR and incident heart failure on patients receiving intensive BP treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A post hoc analysis was conducted on the SPRINT database. Multivariab le Cox regression and interaction restricted cubic spline (RCS) analysis were performed to investigate the interaction between baseline eGFR and intensive BP control on heart failure prevention. The primary endpoint focused on incident heart failure. The study cohort comprised 8369 adults with a mean [SD] age of 68 [59\u201377] years, including 2940 women (35.1%). Over a median [IQR] follow-up period of 3.9 [2.0\u20135.0] years, 183 heart failure events were recorded. A significant interaction was observed between baseline eGFR and treatment groups in terms of heart failure prevention (Interaction P = 0.012). The risk of heart failure showed a sharp slope until eGFR = 75 mL\/min\/1.73 m2 and then became flat by an interaction RCS. Intensive BP treatment did not exhibit a preventive effect on heart failure (HR (95% CI) = 1.03 (0.82\u20131.52)) when baseline eGFR was 75 mL\/min\/1.73 m2 or lower. Conversely, when baseline eGFR was higher than 75 mL\/min\/1.73 m2, a reduced risk of heart failure was observed (HR (95% CI) = 0.65 (0.41\u20130.98)). Intensive BP control did not increase the incident long-term dialysis regardless of baseline eGFR but was associated with a higher risk of eGFR reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among nondiabetic hypertensive patients, baseline eGFR serves as a crucial indicator for assessing the risk reduction potential of intensive BP control in heart failure prevention, with 75 mL\/min\/1.73 m2 appearing as a suitable cut-off value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15232","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T23:48:18Z","timestamp":1737935298000},"page":"2148-2156","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of Baseline eGFR and Incident Heart Failure On Patients Receiving Intensive Blood Pressure Treatment"],"prefix":"10.1093","volume":"12","author":[{"given":"Li","family":"Haonan","sequence":"first","affiliation":[{"name":"Heart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Qiaorui","sequence":"additional","affiliation":[{"name":"Heart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Wenqing","sequence":"additional","affiliation":[{"name":"Tongji University School of Medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Yanjun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shigatse People's Hospital , Tibet ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingcuo","family":"Wangjia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shigatse People's Hospital , Tibet ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shikai","sequence":"additional","affiliation":[{"name":"Heart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deji","family":"Zhuoga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shigatse People's Hospital , Tibet ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Yi","sequence":"additional","affiliation":[{"name":"Heart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5028-9151","authenticated-orcid":false,"given":"Zhao","family":"Yifan","sequence":"additional","affiliation":[{"name":"Heart Center, Shanghai Tenth People's Hospital, School of medicine, Tongji University , Shanghai ,","place":["China"]},{"name":"Department of Cardiology, Shigatse People's Hospital , Tibet ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"2026021804262640500_ehf215232-bib-0001","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/circulationaha.123.065254","article-title":"Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"148","author":"Ostrominski","year":"2023","journal-title":"Circulation"},{"key":"2026021804262640500_ehf215232-bib-0002","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021804262640500_ehf215232-bib-0003","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804262640500_ehf215232-bib-0004","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/eurjpc\/zwae001","article-title":"Remnant cholesterol and intensive blood pressure control in older patients with hypertension: a post hoc analysis of the STEP randomized trial","volume":"31","author":"Yang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026021804262640500_ehf215232-bib-0005","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/ejhf.1971","article-title":"Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy","volume":"23","author":"Vaduganathan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804262640500_ehf215232-bib-0006","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra020676","article-title":"Renal dysfunction complicating the treatment of hypertension","volume":"347","author":"Palmer","year":"2002","journal-title":"N Engl J Med"},{"key":"2026021804262640500_ehf215232-bib-0007","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11886-020-01365-3","article-title":"Intensive BP control and eGFR declines: are these events due to hemodynamic effects and are changes reversible?","volume":"22","author":"Chen","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2026021804262640500_ehf215232-bib-0008","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1681\/asn.2018040365","article-title":"Acute declines in renal function during intensive BP lowering and long-term risk of death","volume":"29","author":"Ku","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026021804262640500_ehf215232-bib-0009","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/hypertensionaha.119.14659","article-title":"Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: a post hoc analysis of the SPRINT and ACCORD-BP randomized controlled trials","volume":"75","author":"Collard","year":"2020","journal-title":"Hypertension"},{"key":"2026021804262640500_ehf215232-bib-0010","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/circulationaha.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2026021804262640500_ehf215232-bib-0011","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1161\/circresaha.123.324001","article-title":"Cardiovascular consequences of uremic metabolites: an overview of the involved signaling pathways","volume":"134","author":"Curaj","year":"2024","journal-title":"Circ Res"},{"key":"2026021804262640500_ehf215232-bib-0012","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2026021804262640500_ehf215232-bib-0013","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/s2352-4642(22)00302-9","article-title":"Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial","volume":"7","author":"Sinha","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2026021804262640500_ehf215232-bib-0014","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s2213-8587(18)30099-8","article-title":"Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials","volume":"6","author":"Beddhu","year":"2018","journal-title":"Llancet Diab Endocrinol"},{"key":"2026021804262640500_ehf215232-bib-0015","doi-asserted-by":"publisher","first-page":"375","DOI":"10.7326\/m16-2966","article-title":"Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial","volume":"167","author":"Beddhu","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026021804262640500_ehf215232-bib-0016","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1161\/circulationaha.115.019657","article-title":"Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the secondary prevention of small subcortical strokes (SPS3) randomized trial","volume":"133","author":"Peralta","year":"2016","journal-title":"Circulation"},{"key":"2026021804262640500_ehf215232-bib-0017","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2023.03.013","article-title":"Acute declines in estimated GFR in blood pressure target trials and risk of adverse outcomes","volume":"82","author":"Ku","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026021804262640500_ehf215232-bib-0018","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012442","article-title":"Impact of renal impairment on intensive blood-pressure-lowering therapy and outcomes in intracerebral hemorrhage: results from ATACH-2","volume":"97","author":"Fukuda-Doi","year":"2021","journal-title":"Neurology"},{"key":"2026021804262640500_ehf215232-bib-0019","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2215\/cjn.0000000000000335","article-title":"Effect of intensive blood pressure control on kidney outcomes: long-term electronic health record-based post-trial follow-up of SPRINT","volume":"19","author":"Drawz","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021804262640500_ehf215232-bib-0020","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"SPRINT Research Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804262640500_ehf215232-bib-0021","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamacardio.2022.4466","article-title":"Predictive utility of a coronary artery disease polygenic risk score in primary prevention","volume":"8","author":"Marston","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026021804262640500_ehf215232-bib-0022","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804262640500_ehf215232-bib-0023","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/s0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2026021804262640500_ehf215232-bib-0024","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1161\/circulationaha.116.025322","article-title":"Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey)","volume":"135","author":"Bress","year":"2017","journal-title":"Circulation"},{"key":"2026021804262640500_ehf215232-bib-0025","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s43587-024-00591-6","article-title":"Incidence and prognosis of cardiac conduction system diseases in hypertension: the STEP trial","volume":"4","author":"Zhao","year":"2024","journal-title":"Nat Aging"},{"key":"2026021804262640500_ehf215232-bib-0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102434","article-title":"Key hypertension breakthroughs and emerging trends from the AHA's scientific sessions","volume":"49","author":"Srikanth","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2026021804262640500_ehf215232-bib-0027","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12944-022-01670-6","article-title":"Association between the atherogenic index of plasma and major adverse cardiovascular events among non-diabetic hypertensive older adults","volume":"21","author":"Hang","year":"2022","journal-title":"Lipids Health Dis"},{"key":"2026021804262640500_ehf215232-bib-0028","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ndt\/gfad139","article-title":"Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models","volume":"39","author":"Tang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804262640500_ehf215232-bib-0029","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/circulationaha.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026021804262640500_ehf215232-bib-0030","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/asn.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026021804262640500_ehf215232-bib-0031","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2148\/66956172\/eschf_12_3_2148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2148\/66956172\/eschf_12_3_2148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:26:36Z","timestamp":1771406796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/2148\/8488349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,26]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15232","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"2024-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}